• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CUSUMIN:一种用于癌症 I 期剂量发现研究的累积和区间设计。

CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies.

机构信息

Statistics and Decision Sciences Japan, Janssen Pharmaceutical K.K., Tokyo, Japan.

Department of Industrial Administration, Tokyo University of Science, Tokyo, Japan.

出版信息

Pharm Stat. 2022 Nov;21(6):1324-1341. doi: 10.1002/pst.2247. Epub 2022 Jul 14.

DOI:10.1002/pst.2247
PMID:35833753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9796866/
Abstract

Recently, model-assisted designs, including the Bayesian optimal interval (BOIN) design with optimal thresholds to determine the dose for the next cohort, have been proposed for cancer phase I studies. Model-assisted designs are useful because of their good performance as model-based designs in addition to their algorithm-based simplicity. In BOIN, escalation and de-escalation based on boundaries can be understood as a type of change point detection based on a sequential test procedure. Notably, the sequential test procedure is used in a wide range of fields and is known for its application to control charts, statistical monitoring methods used for detecting abnormalities in manufacturing processes. In control charts, abnormalities are detected if the control chart statistics are observed to be outside of the optimal boundaries. The cumulative sum (CUSUM) statistic, which is developed for control chart applications, derives higher power under the same erroneous judgment rate. Hence, it is expected that a more efficient model-assisted design can be achieved by the application of CUSUM statistics. In this study, a model-assisted design based on the CUSUM statistic is proposed. In the proposed design, the dose for the next cohort is decided by CUSUM statistics calculated from the counts of the dose-limiting toxicity and pre-defined boundaries, based on the CUSUM control chart scheme. Intensive simulation shows that our proposed method performs better than BOIN, and other representative model-assisted designs, including modified toxicity probability interval (mTPI) and Keyboard, in terms of controlling over-dosing rates while maintaining similar performance in the determination of maximum tolerated dose.

摘要

最近,已经提出了一些模型辅助设计,包括贝叶斯最优区间 (BOIN) 设计,该设计具有确定下一个队列剂量的最优阈值,可用于癌症 I 期研究。模型辅助设计很有用,因为它们除了算法简单之外,作为基于模型的设计也具有良好的性能。在 BOIN 中,基于边界的递增和递减可以理解为一种基于序贯检验过程的变化点检测。值得注意的是,序贯检验过程被广泛应用于多个领域,并且以其在控制图中的应用而闻名,控制图是用于检测制造过程中异常的统计监测方法。在控制图中,如果观察到控制图统计数据超出最优边界,则会检测到异常。累积和 (CUSUM) 统计量是为控制图应用而开发的,在相同错误判断率下具有更高的功效。因此,预计通过应用 CUSUM 统计量可以实现更有效的模型辅助设计。在本研究中,提出了一种基于 CUSUM 统计量的模型辅助设计。在提出的设计中,根据 CUSUM 控制图方案,从剂量限制毒性和预定义边界的计数中计算 CUSUM 统计量,以此来确定下一个队列的剂量。强化模拟表明,我们提出的方法在控制过度剂量率方面优于 BOIN 和其他代表性的模型辅助设计,包括改良毒性概率区间 (mTPI) 和 Keyboard,同时在确定最大耐受剂量方面保持相似的性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf2/9796866/03bf8562c05e/PST-21-1324-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf2/9796866/0cce8cac0490/PST-21-1324-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf2/9796866/86572c2c91ed/PST-21-1324-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf2/9796866/03bf8562c05e/PST-21-1324-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf2/9796866/0cce8cac0490/PST-21-1324-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf2/9796866/86572c2c91ed/PST-21-1324-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf2/9796866/03bf8562c05e/PST-21-1324-g001.jpg

相似文献

1
CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies.CUSUMIN:一种用于癌症 I 期剂量发现研究的累积和区间设计。
Pharm Stat. 2022 Nov;21(6):1324-1341. doi: 10.1002/pst.2247. Epub 2022 Jul 14.
2
On the relative efficiency of model-assisted designs: a conditional approach.论模型辅助设计的相对效率:一种条件方法。
J Biopharm Stat. 2019;29(4):648-662. doi: 10.1080/10543406.2019.1632881. Epub 2019 Jun 29.
3
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.贝叶斯最优区间设计:一种用于I期肿瘤试验的简单且性能良好的设计。
Clin Cancer Res. 2016 Sep 1;22(17):4291-301. doi: 10.1158/1078-0432.CCR-16-0592. Epub 2016 Jul 12.
4
Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.新型 I 期临床试验设计的准确性、安全性和可靠性。
Clin Cancer Res. 2018 Sep 15;24(18):4357-4364. doi: 10.1158/1078-0432.CCR-18-0168. Epub 2018 Apr 16.
5
Incorporating historical information to improve phase I clinical trials.将历史信息纳入以改善 I 期临床试验。
Pharm Stat. 2021 Nov;20(6):1017-1034. doi: 10.1002/pst.2121. Epub 2021 Apr 1.
6
A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials.一项针对I期肿瘤剂量探索试验,比较贝叶斯最优区间(BOIN)设计与3+3区间(i3+3)设计的研究。
Stat Biopharm Res. 2021;13(2):147-155. doi: 10.1080/19466315.2020.1811147. Epub 2020 Sep 14.
7
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.一种基于效用的贝叶斯最优区间(U-BOIN)I/II期设计,用于确定靶向治疗和免疫治疗的最佳生物学剂量。
Stat Med. 2019 Dec 10;38(28):5299-5316. doi: 10.1002/sim.8361. Epub 2019 Oct 17.
8
The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.在样本量较小的剂量发现研究中使用 3+3 设计:陷阱及可能的补救措施。
Clin Trials. 2024 Jun;21(3):350-357. doi: 10.1177/17407745241240401. Epub 2024 Apr 15.
9
Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.用于早期识别最大耐受剂量以加速剂量发现试验的适应性设计。
BMC Med Res Methodol. 2022 Apr 6;22(1):97. doi: 10.1186/s12874-022-01584-y.
10
BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.BOIN-ET:基于疗效和毒性结果的剂量探索的贝叶斯最优区间设计。
Pharm Stat. 2018 Jul;17(4):383-395. doi: 10.1002/pst.1864. Epub 2018 Apr 26.

本文引用的文献

1
SEMIPARAMETRIC DOSE FINDING METHODS FOR PARTIALLY ORDERED DRUG COMBINATIONS.用于部分有序药物组合的半参数剂量寻找方法。
Stat Sin. 2022;32:1983-2005. doi: 10.5705/ss.202020.0248.
2
Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.基于事件时间的贝叶斯最优区间设计加速 I 期临床试验。
Clin Cancer Res. 2018 Oct 15;24(20):4921-4930. doi: 10.1158/1078-0432.CCR-18-0246. Epub 2018 May 16.
3
BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.BOIN-ET:基于疗效和毒性结果的剂量探索的贝叶斯最优区间设计。
Pharm Stat. 2018 Jul;17(4):383-395. doi: 10.1002/pst.1864. Epub 2018 Apr 26.
4
Comparative review of novel model-assisted designs for phase I clinical trials.新型模型辅助设计在 I 期临床试验中的比较综述。
Stat Med. 2018 Jun 30;37(14):2208-2222. doi: 10.1002/sim.7674. Epub 2018 Apr 22.
5
Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.新型 I 期临床试验设计的准确性、安全性和可靠性。
Clin Cancer Res. 2018 Sep 15;24(18):4357-4364. doi: 10.1158/1078-0432.CCR-18-0168. Epub 2018 Apr 16.
6
STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.斯坦因:用于无缝I/II期临床试验的简单毒性和疗效区间设计。
Stat Med. 2017 Nov 20;36(26):4106-4120. doi: 10.1002/sim.7428. Epub 2017 Aug 7.
7
Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials.《键盘:一种用于I期临床试验的新型贝叶斯毒性概率区间设计》
Clin Cancer Res. 2017 Aug 1;23(15):3994-4003. doi: 10.1158/1078-0432.CCR-17-0220. Epub 2017 May 25.
8
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.贝叶斯最优区间设计:一种用于I期肿瘤试验的简单且性能良好的设计。
Clin Cancer Res. 2016 Sep 1;22(17):4291-301. doi: 10.1158/1078-0432.CCR-16-0592. Epub 2016 Jul 12.
9
Bayesian optimal interval design for dose finding in drug-combination trials.药物联合试验中剂量探索的贝叶斯最优区间设计
Stat Methods Med Res. 2017 Oct;26(5):2155-2167. doi: 10.1177/0962280215594494. Epub 2015 Jul 15.
10
Fractional dose-finding methods with late-onset toxicity in phase I clinical trials.I期临床试验中具有迟发性毒性的分次剂量探索方法。
J Biopharm Stat. 2013;23(4):856-70. doi: 10.1080/10543406.2013.789892.